pargyline

简明释义

英[/ˈpɑr.dʒɪ.laɪn/]美[/ˈpɑr.dʒɪ.laɪn/]

n. 巴吉林；优降宁（一种降压药）

英英释义

单词用法

同义词

反义词

例句

1.The combination use of pargyline and reserpine produced different effects on blood pressure of different animal species.

优降宁和利血平联合应用对不同种属动物的血压产生不同的效果。

2.The combination use of pargyline and reserpine produced different effects on blood pressure of different animal species.

优降宁和利血平联合应用对不同种属动物的血压产生不同的效果。

3.The doctor prescribed pargyline to help manage the patient's hypertension.

医生开了pargyline来帮助控制患者的高血压。

4.Research shows that pargyline can have neuroprotective effects in certain conditions.

研究表明，pargyline在某些情况下可以具有神经保护作用。

5.Patients taking pargyline should be monitored for potential side effects.

服用pargyline的患者应监测潜在的副作用。

6.The mechanism of action of pargyline involves the inhibition of monoamine oxidase.

pargyline的作用机制涉及单胺氧化酶的抑制。

7.In clinical trials, pargyline showed promise in treating depression.

在临床试验中，pargyline在治疗抑郁症方面显示出希望。

作文

Pargyline is a monoamine oxidase inhibitor (MAOI) that has been used in the treatment of various neurological disorders. Understanding the role of pargyline in medicine can shed light on how we approach the management of conditions such as depression and Parkinson's disease. As a reversible MAOI, pargyline works by inhibiting the enzyme monoamine oxidase, which is responsible for breaking down neurotransmitters like serotonin, dopamine, and norepinephrine. By preventing this breakdown, pargyline increases the levels of these crucial neurotransmitters in the brain, leading to improved mood and motor function in patients. The history of pargyline dates back to the mid-20th century when researchers were exploring new ways to treat mental health disorders. It was initially developed as an antidepressant, but its applications have expanded over time. One of the significant advantages of pargyline is its selectivity; it primarily targets the brain's monoamine oxidase type B (MAO-B), which makes it particularly beneficial for patients suffering from Parkinson's disease. This selectivity reduces the risk of dietary restrictions commonly associated with other MAOIs, allowing patients to maintain a more normal lifestyle without the fear of hypertensive crises from tyramine-rich foods. In clinical settings, pargyline has demonstrated efficacy in alleviating symptoms of both depression and Parkinson's disease, making it a valuable tool for healthcare providers. However, like all medications, it is not without side effects. Patients may experience headaches, dizziness, or gastrointestinal issues, which necessitate careful monitoring by healthcare professionals. Moreover, the use of pargyline is often accompanied by comprehensive patient education regarding potential interactions with other medications. For instance, combining pargyline with certain antidepressants can lead to serotonin syndrome, a potentially life-threatening condition. Therefore, it is imperative for both patients and doctors to maintain open lines of communication about all medications being taken. Research continues to explore the full potential of pargyline in treating various neurological conditions. Scientists are investigating its effects on cognitive decline and its potential neuroprotective properties. The hope is that pargyline could not only help manage symptoms but also slow the progression of diseases like Alzheimer's and other forms of dementia. In conclusion, understanding pargyline and its mechanisms can lead to better therapeutic strategies for managing neurological disorders. Its role as a reversible MAOI opens up new avenues for treatment, particularly for those who may not respond well to traditional antidepressants. As research advances, the future of pargyline in clinical practice looks promising, potentially offering hope to many patients struggling with mental health and neurological challenges.

Pargyline是一种单胺氧化酶抑制剂（MAOI），已被用于治疗各种神经系统疾病。理解pargyline在医学中的作用可以揭示我们如何处理抑郁症和帕金森病等疾病的管理。作为一种可逆的MAOI，pargyline通过抑制单胺氧化酶这一负责分解神经递质（如血清素、多巴胺和去甲肾上腺素）的酶来发挥作用。通过防止这种分解，pargyline提高了这些关键神经递质在大脑中的水平，从而改善患者的情绪和运动功能。 pargyline的历史可以追溯到20世纪中叶，当时研究人员正在探索治疗心理健康疾病的新方法。它最初被开发为抗抑郁药，但其应用范围随着时间的推移而扩大。pargyline的一个显著优点是其选择性；它主要针对大脑的单胺氧化酶B型（MAO-B），这使得它对患有帕金森病的患者特别有益。这种选择性减少了与其他MAOI相关的饮食限制的风险，使患者能够在不担心富含酪胺食物引发高血压危机的情况下维持更正常的生活方式。 在临床环境中，pargyline已显示出缓解抑郁症和帕金森病症状的有效性，使其成为医疗提供者的重要工具。然而，像所有药物一样，它并非没有副作用。患者可能会经历头痛、头晕或胃肠问题，这需要医疗专业人员的仔细监测。 此外，使用pargyline通常伴随着对潜在药物相互作用的全面患者教育。例如，将pargyline与某些抗抑郁药结合使用可能导致血清素综合症，这是一种潜在的危及生命的情况。因此，患者和医生之间保持开放的沟通渠道对于所有正在服用的药物至关重要。 研究仍在继续探讨pargyline在治疗各种神经系统疾病方面的全部潜力。科学家们正在研究其对认知衰退的影响及其潜在的神经保护特性。希望pargyline不仅能帮助管理症状，还能减缓阿尔茨海默病和其他形式痴呆症的进展。 总之，理解pargyline及其机制可以导致更好的神经系统疾病管理治疗策略。作为一种可逆的MAOI，它为治疗开辟了新的途径，特别是对于那些可能对传统抗抑郁药反应不佳的患者。随着研究的进展，pargyline在临床实践中的未来看起来充满希望，可能为许多面临心理健康和神经挑战的患者提供希望。